PRISMAP sustainability white paper.: Towards PRISMAP+ and a sustainable European medical radionuclide programme

Thomas Cocolios; Sean Collins; Clemens Decristoforo; Charlotte Duchemin; Gilles  de France; Mikael Jensen; Ferid  Haddad; Ulli Koester; Kirsten Leufgen; Mattia  Manzolaro; Nicholas  P. van der Meulen; Renata  Mikolajczak; Bernard  Ponsard; Lucia  Popescu; John O. Prior; Maija Radzina; Thierry  Stora; Zeynep  Talip; David  Viertl; Wolfgang A.  Weber

PRISMAP sustainability white paper. Towards PRISMAP+ and a sustainable European medical radionuclide programme

Thomas Cocolios, Sean Collins, Clemens Decristoforo, Charlotte Duchemin, Gilles de France, Mikael Jensen, Ferid Haddad, Ulli Koester, Kirsten Leufgen, Mattia Manzolaro, Nicholas P. van der Meulen, Renata Mikolajczak, Bernard Ponsard, Lucia Popescu, John O. Prior, Maija Radzina, Thierry Stora, Zeynep Talip, David Viertl, Wolfgang A. Weber

Research output: Book/Report › Commissioned report › peer-review

Abstract

PRISMAP, the European medical radionuclides programme, is a European Commission funded 1 project
delivering research radionuclides produced by eight major European infrastructures. PRISMAP supports
researchers in their home institutes or biomedical institute hubs to accelerate medical research based on
radiopharmaceuticals. PRISMAP has progressed the implementation and harmonisation of the delivery of
these research radionuclides across Europe. PRISMAP radionuclides are made available for submitted
research projects that are selected by a panel of experts on the basis of eligibility criteria,
2 which primarily
relate to the criteria of scientific quality, transnationality and remote access.

Original language	English
Publisher	PRISMAP
Number of pages	9
Publication status	Published - 1 Apr 2024
Externally published	Yes

Field of Science*

3.2 Clinical medicine

Publication Type*

6. Other publications

Access to Document

https://www.prismap.eu/members/repository/Public/PRISMAP_WhitePaper_Public.pdf

Cite this

Cocolios, T., Collins, S., Decristoforo, C., Duchemin, C., de France, G., Jensen, M., Haddad, F., Koester, U., Leufgen, K., Manzolaro, M., P. van der Meulen, N., Mikolajczak, R., Ponsard, B., Popescu, L., Prior, J. O., Radzina, M., Stora, T., Talip, Z., Viertl, D., & Weber, W. A. (2024). PRISMAP sustainability white paper. Towards PRISMAP+ and a sustainable European medical radionuclide programme. PRISMAP. https://www.prismap.eu/members/repository/Public/PRISMAP_WhitePaper_Public.pdf

@book{2af7bcd8a68449b18092cc7ae705595e,

title = "PRISMAP sustainability white paper.: Towards PRISMAP+ and a sustainable European medical radionuclide programme",

abstract = "PRISMAP, the European medical radionuclides programme, is a European Commission funded 1 projectdelivering research radionuclides produced by eight major European infrastructures. PRISMAP supportsresearchers in their home institutes or biomedical institute hubs to accelerate medical research based onradiopharmaceuticals. PRISMAP has progressed the implementation and harmonisation of the delivery ofthese research radionuclides across Europe. PRISMAP radionuclides are made available for submittedresearch projects that are selected by a panel of experts on the basis of eligibility criteria,2 which primarilyrelate to the criteria of scientific quality, transnationality and remote access.",

author = "Thomas Cocolios and Sean Collins and Clemens Decristoforo and Charlotte Duchemin and {de France}, Gilles and Mikael Jensen and Ferid Haddad and Ulli Koester and Kirsten Leufgen and Mattia Manzolaro and {P. van der Meulen}, Nicholas and Renata Mikolajczak and Bernard Ponsard and Lucia Popescu and Prior, {John O.} and Maija Radzina and Thierry Stora and Zeynep Talip and David Viertl and Weber, {Wolfgang A.}",

year = "2024",

month = apr,

day = "1",

language = "English",

publisher = "PRISMAP",

}

Cocolios, T, Collins, S, Decristoforo, C, Duchemin, C, de France, G, Jensen, M, Haddad, F, Koester, U, Leufgen, K, Manzolaro, M, P. van der Meulen, N, Mikolajczak, R, Ponsard, B, Popescu, L, Prior, JO, Radzina, M, Stora, T, Talip, Z, Viertl, D & Weber, WA 2024, PRISMAP sustainability white paper. Towards PRISMAP+ and a sustainable European medical radionuclide programme. PRISMAP. <https://www.prismap.eu/members/repository/Public/PRISMAP_WhitePaper_Public.pdf>

TY - BOOK

T1 - PRISMAP sustainability white paper.

T2 - Towards PRISMAP+ and a sustainable European medical radionuclide programme

AU - Cocolios, Thomas

AU - Collins, Sean

AU - Decristoforo, Clemens

AU - Duchemin, Charlotte

AU - de France, Gilles

AU - Jensen, Mikael

AU - Haddad, Ferid

AU - Koester, Ulli

AU - Leufgen, Kirsten

AU - Manzolaro, Mattia

AU - P. van der Meulen, Nicholas

AU - Mikolajczak, Renata

AU - Ponsard, Bernard

AU - Popescu, Lucia

AU - Prior, John O.

AU - Radzina, Maija

AU - Stora, Thierry

AU - Talip, Zeynep

AU - Viertl, David

AU - Weber, Wolfgang A.

PY - 2024/4/1

Y1 - 2024/4/1

N2 - PRISMAP, the European medical radionuclides programme, is a European Commission funded 1 projectdelivering research radionuclides produced by eight major European infrastructures. PRISMAP supportsresearchers in their home institutes or biomedical institute hubs to accelerate medical research based onradiopharmaceuticals. PRISMAP has progressed the implementation and harmonisation of the delivery ofthese research radionuclides across Europe. PRISMAP radionuclides are made available for submittedresearch projects that are selected by a panel of experts on the basis of eligibility criteria,2 which primarilyrelate to the criteria of scientific quality, transnationality and remote access.

AB - PRISMAP, the European medical radionuclides programme, is a European Commission funded 1 projectdelivering research radionuclides produced by eight major European infrastructures. PRISMAP supportsresearchers in their home institutes or biomedical institute hubs to accelerate medical research based onradiopharmaceuticals. PRISMAP has progressed the implementation and harmonisation of the delivery ofthese research radionuclides across Europe. PRISMAP radionuclides are made available for submittedresearch projects that are selected by a panel of experts on the basis of eligibility criteria,2 which primarilyrelate to the criteria of scientific quality, transnationality and remote access.